|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 21.02 USD | -0.19% |
|
+0.14% | -12.38% |
| May. 20 | Exelixis Settles Cabometyx Patent Litigation with Cipla | MT |
| May. 14 | Transcript : Exelixis, Inc. Presents at 2024 RBC Capital Markets Global Healthcare Conference, May-14-2024 02:35 PM |
Exelixis, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported revenue was USD 425.23 million compared to USD 408.79 million a year ago. Net income was USD 37.32 million compared to USD 40.03 million a year ago.
Basic earnings per share from continuing operations was USD 0.12 compared to USD 0.12 a year ago. Diluted earnings per share from continuing operations was USD 0.12 compared to USD 0.12 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -12.38% | 6.12B | |
| +8.63% | 114B | |
| +13.17% | 107B | |
| -12.76% | 22.22B | |
| -2.33% | 21.28B | |
| -5.15% | 18.8B | |
| -7.19% | 17.51B | |
| -39.93% | 17.17B | |
| +6.67% | 14.14B | |
| +33.90% | 12.2B |
EXELIXIS, INC. 